IBSchek Is Based on Life-Changing Medical Research

Craig Strasnick, president and CEO of Commonwealth Diagnostics International, founded the Massachusetts-based company with his father, Dr. Brian Strasnick, in 2015. He previously served as chief operating officer of the related company Commonwealth Laboratories, Inc. Craig Strasnick and his team continue to lead in the field of gastroenterological diagnostic services, in collaboration with a range of top-flight academic researchers and other businesses.

Among CDI’s recent innovations is the IBSchek system. This blood test assists doctors in the efficient and accurate diagnosis of irritable bowel syndrome (IBS), and is based on pioneering work produced at the GI Motility Program at Cedars-Sinai Medical Center. 

Cedars’ GI Motility Program focuses on research into causes and treatments of common digestive tract problems such as irritable bowel syndrome, acid reflux, incontinence, and constipation. The program can offer patients and physicians a set of diagnostic and treatment options unsurpassed anywhere in the world. 

IBSchek represents a breakthrough in the GI medicine field. In the past, some physicians had considered IBS not an organic problem, but an emotional one. And this most frequent of GI conditions, which affects as many as 15 out of 100 American adults, was previously impossible to definitively diagnose. After eight years of research, the GI Motility Program determined that the most common toxin involved in food poisoning appeared to be the culprit in IBS as well, leading to the development of IBSchek.